Teva Pharmaceutical Faces FTC Investigation for Patents, Washington Post Says
-- The Federal Trade Commission has opened an investigation into Teva
Pharmaceutical Industries over its patent practices, the Washington Post
reported on Monday.
-- The probe focuses on the Israeli company's refusal to withdraw patents for
asthma inhalers and treatments for chronic obstructive pulmonary
disease from a federal registry called the Orange Book, according to the Post.
-- The FTC claims Teva made small modifications to keep the patents in the registry
and stifle competition, the Post reported.
-- Teva spokesperson Kelley Dougherty told The Wall Street Journal that the
company's patents are properly listed and that Teva "continues to stand
behind the company's intellectual property."
Full article at https://www.washingtonpost.com/health/2024/07/01/teva-patent-pharma-generic-inhaler/
Write to Victor Swezey at victor.swezey@wsj.com
(END) Dow Jones Newswires
July 01, 2024 12:49 ET (16:49 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations